Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNAâ˘) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source
No articles found.
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonan...
IRADIMED CORPORATION is a leader in the develop...
Cortexyme is a biopharmaceutical company developing therapeutics based on data sup...
Cortexyme is a biopharmaceutical company develo...
Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company ded...
Arbutus Biopharma is a publicly-traded (NASDAQ:...
Cortexyme is a biopharmaceutical company developing therapeutics based on data sup...
Cortexyme is a biopharmaceutical company develo...
Phoenix PharmaLabs, Inc. (PPL) is a privately held, pre-clinical stage drug develo...
Phoenix PharmaLabs, Inc. (PPL) is a privately h...
NeuBase Therapeutics, Inc. is developing its modular peptide-nucleic acid antisens...
NeuBase Therapeutics, Inc. is developing its mo...
Diffusion Pharmaceuticals is a clinical stage company focused on improving the eff...
Diffusion Pharmaceuticals is a clinical stage c...
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on...
Deciphera Pharmaceuticals is a clinical-stage b...
Curis is a biotechnology company focused on the development and commercialization ...
Curis is a biotechnology company focused on the...
Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing nove...
Provention Bio, Inc. is a clinical-stage biopha...
Join the National Investor Network and get the latest information with your interests in mind.